Skip to main content
SpringerLink
Log in

Industry Technology Assessment: Opportunities and Challenges for Partnership

  • Chapter
Bridges between Science, Society and Policy

Part of the book series: Wissenschaftsethik und Technikfolgenbeurteilung ((ETHICSSCI,volume 22))

  • 219 Accesses

Abstract

This paper draws on experience in the UK pharmaceutical sector to describe a case study on industry approaches to Technology Assessment (TA). Before providing this detail, a general introductory section reviews the European background to TA, identifies some industry trends (with particular reference to experience in Germany) and provides a taxonomy to compare and contrast the public and private sector approaches to TA.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Becks H, Gelbke HP (2001) Die Ökoeffizienz-Analyse nach BASE. In: TA-Datenbank-Nachrichten, No 2, 10. Jahrgang - June 2001, p 34

    Google Scholar 

  • Bouchier A (2003) Industry ponders reimbursement crisis. Nature Biotechnology, 21, 347–348

    Article  Google Scholar 

  • Brochler S, Simonis G, Sunderman K (eds) (1999) Handbuch Technikfolgen-Abschätzung, Sigma, Berlin

    Google Scholar 

  • Buxton M, Hanney SJ (1998) Evaluating the NHS research and development programme: will the programme give value for money? Royal Society of Medicine, 91 (suppl 35), 2–6

    Google Scholar 

  • Cabinet Office (2003) Biosciences: challenges and opportunities for Government, Strategic Futures on http://www.strategy.gov.uk

  • Canning D (2003) New technology in health care. Science in Parliament, 60, 8–9

    Google Scholar 

  • Chapman S, Reeve E, Rajaratnam G, Neary R (2003) Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care. British Medical Journal, 326, 707–709

    Article  Google Scholar 

  • Commie JHJr, Dripps RD (1976) Scientific basis for the support of biomedical science. Science 192, 105–111

    Article  Google Scholar 

  • Dargie C (2000) Policy Futures for UK Health. The Nuffield Trust

    Google Scholar 

  • Department of Health (2003) Our inheritance, our future. Realising the potential of genetics in the NHS

    Google Scholar 

  • Department of Trade and Industry (2002) The 2002 RD Scoreboard

    Google Scholar 

  • DG Enterprise (2003) Innovation Tomorrow, Innovation Paper 28, http://www.cordis.lu/innovation-policy/studies/gen_study7.htm. Editorial, Admitting the evidence, Innovation Policy Review 2003 4, 1–4

  • ESRC (2001) Innovative Health Technologies Programme 2001 on http://www.york.ac.uk/res/iht

  • Fears R, Poste G (1999) Building research resources in human population genetics: the potential of the British National Health Service. Science 284, 267–8

    Article  Google Scholar 

  • Fears R, Tambuyzer E (1999) Core ethical values for European bioindustries. Nature Biotechnology 17, 114–115

    Article  Google Scholar 

  • Fears R, Roberts D, Poste G (2000) Rational or rationed medicine? The promise of genetics for improved clinical practice. British Medical J. 320, 933–935

    Article  Google Scholar 

  • G10 Medicines Group, High Level Group on innovation and provision of medicines in the European Union. Recommendations for action, May 2002 on http://europa.eu.int/comm/health/ ph/key_doc/key08_en.pdf

    Google Scholar 

  • Gelijns AC, Rosenberg N, Moskowitz Al (1998) Capturing the unexpected benefits of medical research. New Engl J. Med. 339, 693–698

    Google Scholar 

  • Grunwald A (2002) Technikfolgenabschätzung - eine Einführung. Sigma, Berlin

    Google Scholar 

  • Hennen L (1999) Technology Assessment - does it always come “too late”? In: TAB-Brief, No 17

    Google Scholar 

  • Lasker Charitable Trust, Exceptional Returns - The Economic Value of America’s Investment in Medical Research, 2000 on http://www.fundingfirst.org

  • Martin S (2003) The evaluation of strategic research partnerships. Technology Analysis and Strategic Management 15, 159–176

    Article  Google Scholar 

  • Medical Technologies Group, Enhancing patient access to new medical technologies. Science in Parliament 2003 60, 20–21

    Google Scholar 

  • Miller DH (2003) Commentary: Evaluating disease modifying treatments in multiple sckerosis. British Medical J. 326, 525

    Google Scholar 

  • Minx E (2001) In: TA-Datenbank-Nachrichten, No 2, 10. Jahrgang, p 39

    Google Scholar 

  • Morris N (2001) The changing landscape of regulatory control of biological medicines. Technology Analysis Strategic Management 13, 246–263

    Google Scholar 

  • NIH, NIH GPRA Research Programmes Outcome FY 1999 Assessment Material on wwwl.od.nih.gov/gpra accessed on 3 December 2002

    Google Scholar 

  • Nuffield Council on Bioethics, Consultation on pharmacogenetics: ethical issues, 2002 on http://www.nuffieldbioethics.org/pharmacogenetics/public.asp

  • OECD, The OECD Health Project relating to new and emerging health related technologies on www.oecd.org accessed 24 March 2003

    Google Scholar 

  • Pardes H, Manton KG, Lander ES, Tolley D, Ullian AD, Palmer H (1999) Effects of medical research on health care and the economy. Science 283, 36–37

    Article  Google Scholar 

  • Pharmaceutical Industry Competitiveness Task Force, Final Report March 2001, Department of Health and Association of British Pharmaceutical Industry websites

    Google Scholar 

  • Postnote 168 MS treatments and NICE, Parliamentary Office of Science and Technology 2002

    Google Scholar 

  • Pullman D, Lotus A (2003) Clinical trials, genetic add-ons, and the question of benefit-sharing. Lancet 362, 242–244

    Article  Google Scholar 

  • Richards T (1999) The genomic challenge. British Medical J. 318, 341–342

    Article  Google Scholar 

  • Ropohl G (1999) Innovative Technikbewertung. In: Brochler S, Simonis G, Sundermann K (eds) Handbuch Technikfolgen-Abschätzung. Sigma, Berlin

    Google Scholar 

  • Roses A (2003) Pharmacogenetics: personalised safety and segmented efficacy on http://www.acmedsci.ac.uk/forum.roses.htm and related articles cited therein

  • Royal College of Physicians (2000) The prescribing of costly medicines

    Google Scholar 

  • Royal Pharmaceutical Society of Great Britain, Nuffield Council on Bioethics. Consultation on pharmacogenetics: ethical issues on http://www.rpsgb.org.uk/pdfs/pharmacogene.pdf accessed on 17 February 2003

  • Salmankaita JP, Salo A (2002) Rationales for government intervention in the commercialization of new technologies. Technology Assessment Strategic Management 14, 183–200

    Article  Google Scholar 

  • Salo A, Kuusi O (2001) Developments in parliamentary technology assessment in Finland Science Public Policy 28, 453–464

    Google Scholar 

  • Stein JA (2002) Science, technology and European foreign policy: European integration, global interaction. Science Public Policy 29, 463–477

    Article  Google Scholar 

  • Steinmuller K, Tacke K, Tschiedel R (1999) Innovationsorientierte Technikfolgenabschatzung. In: Brochler S, Simonis G, Sundermann K (eds) Handbuch Technikfolgennabschätzung, Band 1. Sigma, Berlin 129–145

    Google Scholar 

  • Vaccani P, Bax R, Watson P (1997) Measuring outcomes from RD in healthcare. In: Anderson J, Fears R, Taylor B (eds) Managing technology for competitive advantage. Cartermill, London 379–399

    Google Scholar 

  • Wanless D (2001) Securing our future health: taking a long-term view on http://www.hmtreasury.gov.uk/Consultations_Legisl…/consult_wanless_index.cf

  • Weber J, Schaffer U, Hoffmann D, Kehnnann T (1999) Technology Assessment — Eine Managementperspektive — Bestandsaufnahme, Analyse, Handlungsempfehlungen. Gabler, Wiesbaden

    Google Scholar 

  • Zimmern R, Cook C (2000) Genetics and Health. The Nuffield Trust

    Google Scholar 

Download references

Authors
  1. Robin Fears
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susanne Stephan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Technikfolgenabschätzung und Systemanalyse (Institute for Technology Assessment and System Analysis), Forschungszentrum Karlsruhe, P.O. box 36 40, 76021, Karlsruhe, Germany

    Michael Decker

  2. Europäische Akademie GmbH, Wilhelmstraße 56, 53474, Bad Neuenahr-Ahrweiler, Germany

    Miltos Ladikas , Susanne Stephan  & Friederike Wütscher ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Fears, R., Stephan, S. (2004). Industry Technology Assessment: Opportunities and Challenges for Partnership. In: Decker, M., Ladikas, M., Stephan, S., Wütscher, F. (eds) Bridges between Science, Society and Policy. Wissenschaftsethik und Technikfolgenbeurteilung, vol 22. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-06171-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-06171-8_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-05960-5

  • Online ISBN: 978-3-662-06171-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation